Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 59Squamous Cell Carcinoma of Head and Neck 32Carcinoma, Non-Small-Cell Lung 29Neoplasms 26Head and Neck Neoplasms 26Colonic Neoplasms 20Neoplasm Metastasis 17Rectal Neoplasms 12Breast Neoplasms 11Lung Neoplasms 10Pancreatic Neoplasms 9Carcinoma, Squamous Cell 6Tongue Neoplasms 5Salivary Gland Neoplasms 5Melanoma 5Stomach Neoplasms 4Solid Tumors 4Ovarian Neoplasms 4Carcinoma, Renal Cell 4Advanced Solid Tumor 4Triple Negative Breast Neoplasms 3Sarcoma 3Kidney Neoplasms 3Endometrial Neoplasms 3Advanced Cancers 3Uterine Cervical Neoplasms 2Thyroid Neoplasms 2Recurrence 2Pharyngeal Neoplasms 2Neoplasms by Site 2

Interventions

Gemcitabine 20Cisplatin 17pembrolizumab 11Magnetic Resonance Spectroscopy 7durvalumab 5Platinum 5Irinotecan 5Fluorouracil 51,2-diaminocyclohexaneplatinum II citrate 5Leucovorin 4Taxes 3Oxaliplatin 3Nivolumab 3Fluorodeoxyglucose F18 3Carboplatin 3Biopsy 3Bevacizumab 3spartalizumab 2pemigatinib 2ivosidenib 2fludarabine 2budigalimab 2atezolizumab 2Specimen Handling 2Radiosurgery 2Paclitaxel 2Immunoglobulin G 2Floxuridine 2FAPI-46 2Disulfides 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Cholangiocarcinoma × Cetuximab × Clear all
NCT06607185 2026-05-26

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
750 enrolled
GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡